Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 3;10(6):340.
doi: 10.3390/brainsci10060340.

Clinical Manifestation of Juvenile and Pediatric HD Patients: A Retrospective Case Series

Affiliations

Clinical Manifestation of Juvenile and Pediatric HD Patients: A Retrospective Case Series

Jannis Achenbach et al. Brain Sci. .

Abstract

Background: Studies on the clinical manifestation and course of disease in children suffering from Huntington's disease (HD) are rare. Case reports of juvenile HD (onset ≤ 20 years) describe heterogeneous motoric and non-motoric symptoms, often accompanied with a delay in diagnosis. We aimed to describe this rare group of patients, especially with regard to socio-medical aspects and individual or common treatment strategies. In addition, we differentiated between juvenile and the recently defined pediatric HD population (onset < 18 years).

Methods: Out of 2593 individual HD patients treated within the last 25 years in the Huntington Centre, North Rhine-Westphalia (NRW), 32 subjects were analyzed with an early onset younger than 21 years (1.23%, juvenile) and 18 of them younger than 18 years of age (0.69%, pediatric).

Results: Beside a high degree of school problems, irritability or aggressive behavior (62.5% of pediatric and 31.2% of juvenile cases), serious problems concerning the social and family background were reported in 25% of the pediatric cohort. This includes an attempted rape and robbery at the age of 12, as problems caused by the affected children, but also alcohol-dependency in a two-year-old induced by a non-HD affected stepfather. A high degree of suicidal attempts and ideations (31.2% in pediatric and 33.3% in juvenile group) was reported, including drinking of solvents, swallowing razor blades or jumping from the fifth floor with following incomplete paraparesis. Beside dopaminergic drugs for treatment of bradykinesia, benzodiazepines and tetrabenazine for treatment of dystonia, cannabinoids, botulinum toxin injection and deep brain stimulation were used for the improvement of movement disorders, clozapine for the treatment of tremor, and dopa-induced hallucinations and zuclopenthixole for the treatment of severe aggressive behavior.

Conclusions: Beside abnormalities in behavior from an early age due to HD pathology, children seem to have higher socio-medical problems related to additional burden caused by early affected parents, instable family backgrounds including drug abuse of a parent or multiple changes of partners. Treatment required individualized strategies in many cases.

Keywords: case series; early-onset Huntington’s disease; juvenile Huntington’s disease; pediatric Huntington’s disease.

PubMed Disclaimer

Conflict of interest statement

Saft reports personal fees/honoraria from Teva Pharma GmbH, as well as non-financial support and other support from ENROLL-HD study (CHDI), PRIDE-HD (TEVA), LEGATO (TEVA), and Amaryllis (Pfizer), ASO (IONIS Pharmaceuticals and Roche AG) for the conducting of studies and grants from Biogen all outside the submitted work and without relevance to the manuscript. The other authors declare they have no conflict of interest concerning the research related to this manuscript.

References

    1. Walker F. Huntington’s disease. Lancet. 2007;369:218–228. doi: 10.1016/S0140-6736(07)60111-1. - DOI - PubMed
    1. Roos R.A. Huntington’s disease: A clinical review. Orphanet J. Rare Dis. 2010;5:40. doi: 10.1186/1750-1172-5-40. - DOI - PMC - PubMed
    1. Quarrell O., Nance M.A., Nopoulos P., Paulsen J.S., Smith J.A., Squitieri F. Managing juvenile Huntington’s disease. Neurodegener. Dis. Manag. 2013;3:267–276. doi: 10.2217/nmt.13.18. - DOI - PMC - PubMed
    1. Quarrell O., Nance M.A., Nopoulos P., Reilmann R., Oosterloo M., Tabrizi S.J., Furby H., Saft C., Roos R.A.C., Squitieri F., et al. Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease? Mov. Disord. 2019;34:584–585. doi: 10.1002/mds.27640. - DOI - PubMed
    1. Kieburtz K., Penney J.B., Corno P., Ranen N., Shoulson I., Feigin A., Abwender D., Timothy Greenarnyre J., Higgins D., Marshall F.J., et al. Unified Huntington’s disease rating scale: Reliability and consistency. Mov. Disord. 1996;11:136–142. doi: 10.1002/mds.870110204. - DOI - PubMed

LinkOut - more resources